Phase I clinical and pharmacokinetic study of menogaril (7-con-O-methylnogarol) in previously treated patients with acute leukemia

Constance Mazurek, Janice P. Dutcher, Edward L. Schwartz, Susan Garl, Laura Benson, Peter H. Wiernik

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Fifteen patients with relapsed or refractory acute leukemia were treated in this phase I study of menogaril (7-con-O-methylnogarol), a nogalamycin anthracycline derivative. Doses ranged from 50 mg/m2/day to 130 mg/m2/day, administered daily for 5 days. Pharmacokinetic studies were performed at each dose level and confirmed the findings of pharmacokinetic data derived from previous studies in patients with solid tumors. All patients experienced grade 4 hematologic toxicity and the dose limiting toxicity was mucositis. Two patients, one with acute myeloid leukemia and one with acute lymphoid leukemia, achieved complete responses. The AML complete response lasted 10 months and the ALL patient died in CR at 2 + months. Both patients were treated at a dose of 100 mg/m2/day for five days. At this dose, a second induction or consolidation course could be given without severe mucositis, and this is the dose recommended for further phase II studies in leukemia using this schedule.

Original languageEnglish (US)
Pages (from-to)313-322
Number of pages10
JournalInvestigational New Drugs
Volume11
Issue number4
DOIs
StatePublished - Dec 1993

Fingerprint

Menogaril
Leukemia
Pharmacokinetics
Mucositis
Nogalamycin
Anthracyclines
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Clinical Studies
Appointments and Schedules

Keywords

  • acute leukemia
  • anthracycline
  • menogaril
  • pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Phase I clinical and pharmacokinetic study of menogaril (7-con-O-methylnogarol) in previously treated patients with acute leukemia. / Mazurek, Constance; Dutcher, Janice P.; Schwartz, Edward L.; Garl, Susan; Benson, Laura; Wiernik, Peter H.

In: Investigational New Drugs, Vol. 11, No. 4, 12.1993, p. 313-322.

Research output: Contribution to journalArticle

Mazurek, Constance ; Dutcher, Janice P. ; Schwartz, Edward L. ; Garl, Susan ; Benson, Laura ; Wiernik, Peter H. / Phase I clinical and pharmacokinetic study of menogaril (7-con-O-methylnogarol) in previously treated patients with acute leukemia. In: Investigational New Drugs. 1993 ; Vol. 11, No. 4. pp. 313-322.
@article{c65d018658ca458995e4a628a3f3c7c0,
title = "Phase I clinical and pharmacokinetic study of menogaril (7-con-O-methylnogarol) in previously treated patients with acute leukemia",
abstract = "Fifteen patients with relapsed or refractory acute leukemia were treated in this phase I study of menogaril (7-con-O-methylnogarol), a nogalamycin anthracycline derivative. Doses ranged from 50 mg/m2/day to 130 mg/m2/day, administered daily for 5 days. Pharmacokinetic studies were performed at each dose level and confirmed the findings of pharmacokinetic data derived from previous studies in patients with solid tumors. All patients experienced grade 4 hematologic toxicity and the dose limiting toxicity was mucositis. Two patients, one with acute myeloid leukemia and one with acute lymphoid leukemia, achieved complete responses. The AML complete response lasted 10 months and the ALL patient died in CR at 2 + months. Both patients were treated at a dose of 100 mg/m2/day for five days. At this dose, a second induction or consolidation course could be given without severe mucositis, and this is the dose recommended for further phase II studies in leukemia using this schedule.",
keywords = "acute leukemia, anthracycline, menogaril, pharmacokinetics",
author = "Constance Mazurek and Dutcher, {Janice P.} and Schwartz, {Edward L.} and Susan Garl and Laura Benson and Wiernik, {Peter H.}",
year = "1993",
month = "12",
doi = "10.1007/BF00874430",
language = "English (US)",
volume = "11",
pages = "313--322",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "4",

}

TY - JOUR

T1 - Phase I clinical and pharmacokinetic study of menogaril (7-con-O-methylnogarol) in previously treated patients with acute leukemia

AU - Mazurek, Constance

AU - Dutcher, Janice P.

AU - Schwartz, Edward L.

AU - Garl, Susan

AU - Benson, Laura

AU - Wiernik, Peter H.

PY - 1993/12

Y1 - 1993/12

N2 - Fifteen patients with relapsed or refractory acute leukemia were treated in this phase I study of menogaril (7-con-O-methylnogarol), a nogalamycin anthracycline derivative. Doses ranged from 50 mg/m2/day to 130 mg/m2/day, administered daily for 5 days. Pharmacokinetic studies were performed at each dose level and confirmed the findings of pharmacokinetic data derived from previous studies in patients with solid tumors. All patients experienced grade 4 hematologic toxicity and the dose limiting toxicity was mucositis. Two patients, one with acute myeloid leukemia and one with acute lymphoid leukemia, achieved complete responses. The AML complete response lasted 10 months and the ALL patient died in CR at 2 + months. Both patients were treated at a dose of 100 mg/m2/day for five days. At this dose, a second induction or consolidation course could be given without severe mucositis, and this is the dose recommended for further phase II studies in leukemia using this schedule.

AB - Fifteen patients with relapsed or refractory acute leukemia were treated in this phase I study of menogaril (7-con-O-methylnogarol), a nogalamycin anthracycline derivative. Doses ranged from 50 mg/m2/day to 130 mg/m2/day, administered daily for 5 days. Pharmacokinetic studies were performed at each dose level and confirmed the findings of pharmacokinetic data derived from previous studies in patients with solid tumors. All patients experienced grade 4 hematologic toxicity and the dose limiting toxicity was mucositis. Two patients, one with acute myeloid leukemia and one with acute lymphoid leukemia, achieved complete responses. The AML complete response lasted 10 months and the ALL patient died in CR at 2 + months. Both patients were treated at a dose of 100 mg/m2/day for five days. At this dose, a second induction or consolidation course could be given without severe mucositis, and this is the dose recommended for further phase II studies in leukemia using this schedule.

KW - acute leukemia

KW - anthracycline

KW - menogaril

KW - pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0027772609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027772609&partnerID=8YFLogxK

U2 - 10.1007/BF00874430

DO - 10.1007/BF00874430

M3 - Article

C2 - 8157473

AN - SCOPUS:0027772609

VL - 11

SP - 313

EP - 322

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 4

ER -